Search Results for "Neosar"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Neosar. Results 1 to 3 of 3 total matches.

Recombinant Interleukin-11 for Chemotherapy-Induced Thrombocytopenia

   
The Medical Letter on Drugs and Therapeutics • Jul 31, 1998  (Issue 1032)
(Cytoxan, Neosar) and doxorubicin (Adriamycin, and others) found that 27 of 40 patients (68%) randomized ...
The US Food and Drug Administration (FDA) has approved use of recombinant human interleukin 11 (rhIL-11; oprelvekin; Neumega - Genetics Institute) to increase platelet counts and decrease the need for platelet transfusions in patients with severe thrombocytopenia caused by chemotherapy for nonmyeloid malignancies.
Med Lett Drugs Ther. 1998 Jul 31;40(1032):75-7 |  Show IntroductionHide Introduction

Drugs of Choice for Cancer

   
Treatment Guidelines from The Medical Letter • Mar 01, 2003  (Issue 7)
infiltrates Oncology; Neosar – Pharmacia) taste with IV administration; visual blurring and fibrosis ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Treat Guidel Med Lett. 2003 Mar;1(7):41-52 |  Show IntroductionHide Introduction

Drugs of Choice for Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 1995  (Issue 945)
-Myers Oncology; Neosar − Pharmacia) Nausea and vomiting; Type I (anaphylactoid) hypersensitivity ...
Med Lett Drugs Ther. 1995 Mar 31;37(945):25-32 |  Show IntroductionHide Introduction